

Jun 05, 2025

Version 2

# SARS-CoV-2 nsp3 macrodomain expression and purification protocol for crystallization V.2

 Version 1 is forked from [Zika NS5 RdRp His-SUMO construct small scale expression and purification protocol](#)

DOI

[dx.doi.org/10.17504/protocols.io.dm6gpz9xplzp/v2](https://dx.doi.org/10.17504/protocols.io.dm6gpz9xplzp/v2)

Korvus Wang<sup>1</sup>, Michael Fairhead<sup>1</sup>, Eleanor Williams<sup>1</sup>

<sup>1</sup>Centre for Medicines Discovery, University of Oxford, ASAP Discovery Consortium

ASAP Discovery



Korvus Wang

CMD

## Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

[Create free account](#)

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.dm6gpz9xplzp/v2>

**Protocol Citation:** Korvus Wang, Michael Fairhead, Eleanor Williams 2025. SARS-CoV-2 nsp3 macrodomain expression and purification protocol for crystallization. [protocols.io https://dx.doi.org/10.17504/protocols.io.dm6gpz9xplzp/v2](https://dx.doi.org/10.17504/protocols.io.dm6gpz9xplzp/v2) Version created by [Mary-Ann Xavier](#)

**License:** This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

**Protocol status:** Working

We use this protocol and it's working

**Created:** June 05, 2025

**Last Modified:** June 05, 2025

**Protocol Integer ID:** 219642

**Keywords:** expression, purification, ASAP, CMD, AViDD, SARS-CoV-2, SARS-CoV-2 nsp3, SARS-CoV-2 nsp3 macrodomain, SARS-CoV-2 macrodomain, nsp3 macrodomain, macrodomain, mac1, his-tag, purification of sar, purification protocol for crystallization, crystallization, sar, purification protocol, purification, addgene id

**Funders Acknowledgements:**

National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)

Grant ID: U19AI171399

## Disclaimer

Research was supported in part by NIAID of the U.S National Institutes of Health under award number U19AI171399. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

## Abstract

This protocol details the expression and purification of SARS-CoV-2 nsp3 macrodomain crystallization construct bearing a N-terminal His-tag at small scale (<6L). In this new version we added the Addgene id.

## Attachments



PDF

[PAGE24-00789 -](#)

[CVNSP...](#)

493KB

## Guidelines

- Construct / plasmid resource-name:** SARS-CoV-2 nsp3 macrodomain crystallization construct bearing a N-terminal His-tag.

## Materials

### Plasmid details:

- Vector: pNIC28-Bsa4
- Cell line: E. coli Rosetta strain BL21(DE3)-RR
- Tags and additions: N-terminal His-tag
- Construct protein sequence:

MHHHHHHSSGVLDGTENLYFQSMVNSFSGYLKLTNDVYIKNADIVEAKKVKPTVVNAANVYLKHGGGVAGALNKAT  
NNAMQVESDDYIATNGPLKVGGSCLSGHNLAKHCLHVVGPNVNKGEDIQLLKSAYENFNQHEVLLAPLLSAGIFGADPI  
HSLRVCVDTVRTNVYLAFFDKNLYDKLVSSFL

### Expression

TB media, mM IPTG

### Purification

Chicken hen egg white lysozyme

Benzonase

Imidazole

Ni Sepharose 6 FF resin

Gravity flow column, 2.5 cm diameter

Centrifugal concentrators, 30 kDa MWCO

On an FPLC system:

Cytiva HiLoad 16/600 Superdex 75 pg

5mL sample loop

HiPrep 26/10 deasalting column

SDS-PAGE sample buffer, gel, and gel tank

### Lysis buffer:

	A	B
	Hepes (pH 7.5)	50 mM
	NaCl	500 mM
	Glycerol	5%
	TCEP	0.5 mM
	Lysozyme	0.5 mg/mL
	Benzonase	0.05 mg/mL

Prepare 100L per 1L E.coli expression

**Base buffer:**

	A	B
	Hepes (pH 7.4)	50 mM
	NaCl	500 mM
	Glycerol	5%
	TCEP	0.5 mM

Prepare 2L per 6L E.coli expression. Used to prepare the following buffers

**Binding buffer:** base buffer**Wash buffer:** base buffer + 20 mM imidazole**Elution buffer:** base buffer, add 500 mM imidazole**Gel filtration buffer:** base buffer**SDS-PAGE gel:** NuPage 4-12%, Bis-Tris protein gel, 27 well.

Run in MES buffer, 200V 35mins.

## Protocol materials

 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolate:Wuhan-Hu-1 nsp3  
macrodomain addgene Catalog #228643

## Troubleshooting

## Abbreviations

- 1 CV - column volume, total volume of resin in a column  
IMAC - immobilised metal affinity chromatography  
FT - flow through  
CVNSP3mac1 - SARS-CoV-2 nsp3 macrodomain

## Plasmid Transformation

1d

- 2 CVNSP3mac1 N-terminal His-tagged construct was inoculated from its BL21(DE3)-RR glycerol stock.


 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolate:Wuhan-Hu-1 nsp3 macrodomain **addgene Catalog #228643**

### Note

The His-tagged CVNSP3mac1 construct encodes the SARS-CoV-2 nsp3 macrodomain with a N-terminal His tag fusion on a kanamycin resistant plasmid backbone with a T7 promoter.

## Protein expression

2d 10h

- 3 Scrape off some of the glycerol stock with a sterile loop and use this to inoculate a 50 mL falcon tube containing  10 mL of LB supplemented with  50 Mass Percent kanamycin. Grow the starter culture at  37 °C  Overnight with 200 rpm shaking.
- 4 Use the  10 mL starter culture to inoculate  1 L TB media (see Materials) supplemented with  50 Mass Percent kanamycin in a baffled flask.  
 200 rpm, 37°C

4h

6h



### Note

For this protocol 6L of pellet was grown for purification.

5 When the OD<sub>600</sub> reaches approximately 1.4, reduce temperature to  18 °C and incubate for an additional hour. Add  [M] 0.4 millimolar (mM) IPTG. Lower shaker speed to  180 rpm, 18°C. Incubate  Overnight.

1d



6 Harvest the cell by centrifugation at  4000 x g, 4°C, 00:30:00. Discard supernatant and store pellet by freezing at  -80 °C.

30m

## Protein Purification

2d

### 7 Lyse cell pellet

2h 30m

7.1

1h

#### Note

See Materials tab for buffer compositions.

#### Note

His-tagged CVNSP3mac1 construct properties

**Before tag cleavage:**

MW = 20.623 kDa

E (assume all Cys reduced) = 11920 mM<sup>-1</sup>cm<sup>-1</sup>

PI = 6.70

**After tag cleavage:**

MW = 18.158 kDa

E (assume all Cys reduced) = 10430

PI = 7.30

These values are determined by Expasy ProtParam

Thaw and resuspend the pellet in ~7mL of lysis buffer per g of pellet. Stir gently with magnetic stir bar at  Room temperature for  00:30:00 to allow lysozyme and bezonase to start breaking down

cell components.

7.2 Lyse by sonication  00:00:02 On  00:00:04 Off for a total 'on' time of 10m 6s  00:10:00 at 40% amplitude to fully rupture the cells. Ensure pellet is  0 °C during sonication to prevent overheating.

7.3 Centrifuge the lysed cells for  38000 x g, 4°C, 01:00:00 to remove insoluble cell debris, and collect supernatant in a bottle  4 °C 1h

## 8 Perform IMAC to extract target protein from the lysed cell mixture

8.1 Dispense  2 mL Nickle affinity resin Ni Sepharose 6 FF - Cytiva into a gravity flow column. Equilibrate resin by first rinsing with ~  10 µL distilled water, then ~  10 µL binding buffer to remove the storage solution. 10m

8.2 Resuspend the equilibrated resin with some binding buffer and add to the supernatant bottle. Incubate the resin with the supernatant for  01:00:00 while rotating or otherwise mixing gently at  4 °C 1h

8.3 Load the resin/supernatant mix back onto the gravity flow column, retaining the FT separately for SDS-PAGE analysis. 30m

### Note

For SDS-PAGE samples, mix 15 µL sample with 5 µL 4x sample buffer, supplemented with 10mM DTT.

8.4 Wash the column with  10 µL of base buffer, followed by  10 µL of wash buffer twice. Allow wash buffer to pass through completely between washes. This is to remove non-specific, weak binding of contaminant proteins from the resin for a cleaner elution. Collect washes separately for SDS-PAGE analysis. 30m

8.5 Elute the protein with  7.5 mL of elution buffer. 20m

8.6 Repeat step 8.5 one more time, collecting a total of 2 separate elution fractions. This is to ensure maximum retrieval of protein from the resin. 20m

Measure the total protein concentration of the elutions by Nanodrop. Although still a mixture, A280 value can give an estimate of the protein content, which will determine how much protease need to be added to remove the affinity tag.

8.7 Wash used IMAC resin with 10 CV of base buffer, and leave in the column submerged in a small amount of base buffer such that the resin is kept moist.

This washed IMAC resin will later be reused for reverse IMAC (rIMAC)

9 Run SDS-PAGE of all samples from total lysis supernatant to final elution. Stain gel with protein staining solution Coomassie Blue and determine which fractions contain the target protein by finding the band corresponding to the target molecular weight.

40m

#### Note

The target protein is expected to be present mostly in the elution samples, although small amounts may be found in the FT and washes.

If that is not the case, then further troubleshooting is required.

## 10 Elution de-salting, tag cleavage and reverse IMAC

1d

10.1 Pool the elutions and desalt using a HiPrep 26/10 desalting column, run on an AKTA pure at a maximum flow rate of 10mL/min.

30m

#### Note

Desalting reduces the concentration of imidazole in the sample which may inhibit TEV protease activity during tag cleavage as well as interfering with the reverse IMAC step.

10.2 For tag removal, His-TEV was added in 1:20 ratio to the total protein content of the diluted sample, as determined by nanodrop. The mixture was left standing in the cold room at  4 °C  Overnight

1d

#### Note

TEV:total protein ratio increased due to previous difficulty with tag cleavage for this construct. TEV addition at the standard 1:100 ratio left the majority of His-tagged CVNSP3mac1 uncleaved after overnight cold incubation.

10.3 In morning, pour the cleavage mixture over the washed resin three times and collect final FT.

30m


**Note**

This step will remove the cleaved tag and any uncleaved target from the sample. If the protease used is His-tagged, then the protease is removed from sample too.

Previous purification where the cleavage mixture was incubated with the rIMAC resin while rotating for 30mins in cold resulted in protein precipitation. No such issue observed when passing mixture through resin three times.

10.4 Take samples of the rIMAC FT and wash and characterise content by SDS-PAGE

30m



**SDS-PAGE analysis of IMAC and cleavage fractions.** The major band in rIMAC FT agrees with the size of the cleaved construct (18.158 kDa)

10.5 (Optional) elute rIMAC resin with  $\text{2 } \mu\text{L}$  elution buffer to confirm if the protein shows non-specific binding to the resin used. 5m

**Note**

This will help determine if the protein is "sticky" to the Ni resin matrix material, and help in further troubleshooting if the final yield is lower than expected.

## 11 Purify sample further by size exclusion chromatography. 6h

11.1 Using 10,000 MWCO spin concentrators, concentrate the rIMAC step containing fractions of the target protein to a final volume of under  5 mL. 1h

11.2 Remove any solid aggregates from the sample by centrifugation at  17200 x g, 4°C, 00:10:00, then immediately draw up the supernatant with a 5mL syringe and a blunt-tip fill needle, taking care not to disturb the pellet. 15m

### Note


This is to remove as much solid particles from the injection sample as possible, so as to not clog the in-line filter or frit of the column.

## 12 Using the AKTA Pure system: 2h


Inject the sample onto a 5 mL sample loop.

Run the sample down HiLoad 16/60 Superdex 75 pg gel filtration column at 1 mL/min in gel filtration buffer, collecting 1 mL aliquots.

## 13 From the chromatogram, fraction F9-H8 analyse by SDS-PAGE. 1h



**Chromatogram of the CVNSP3mac1 SEC run.** Fractions D7 and F10-G8 were analyzed by SDS-PAGE to see which contained the target protein




**SDS-PAGE analysis of SEC fraction D7 and F10-G8.** Fractions F9-G8 were pooled as they contain majority target protein in comparison to contaminants.

13.1 Take the fractions that contain the target protein, which in this case are fraction F9-G8. Concentrate the final sample in Vivaspin 500 10 kDa MWCO centrifugal concentrator until the concentration reaches > [M] 45 mg/mL.

30m

Take  1  $\mu$ L of the final sample for SDS-PAGE, which was not carried out here. However, intact MS confirms sample purity.



**Intact mass spectroscopy result of the purified CVNSP3mac1 sample.** The major peak (18.158 kDa) agrees with the no-tag molecular weight of CVNSP3mac1 (18.158 kDa).

13.2 Aliquot into appropriate volumes for future usage to minimise freeze/thaw cycles. Flash-freeze in liquid nitrogen, and store at  -80 °C until required.

10m